4-Jun-2026
BeOne Medicines Ltd (6160) Gets a Buy from CICC
TipRanks (Thu, 4-Jun 9:48 PM ET)
BeOne Medicines Rocked by Fresh Insider Stock Sale From Boardroom Heavyweight
TipRanks (Wed, 3-Jun 10:06 PM ET)
Citi Keeps Their Buy Rating on BeOne Medicines Ltd (6160)
TipRanks (Wed, 3-Jun 8:26 PM ET)
TipRanks (Wed, 3-Jun 2:00 PM ET)
BeOne Medicines Halts Early KRAS Trial, Resetting Expectations in a Crowded Oncology Race
TipRanks (Wed, 3-Jun 12:31 PM ET)
Zymeworks and BeOne: Long-Term Cancer Study Update Supports Durable Drug Story
TipRanks (Wed, 3-Jun 12:31 PM ET)
Most and least shorted mid- to mega-cap healthcare stocks at the end of May
Seeking Alpha News (Wed, 3-Jun 9:35 AM ET)
Wolfe Research Sticks to Its Buy Rating for BeOne Medicines (ONC)
TipRanks (Wed, 3-Jun 8:40 AM ET)
Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)
TipRanks (Wed, 3-Jun 4:17 AM ET)
TipRanks (Tue, 2-Jun 9:00 AM ET)
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
Beone Medicines Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ONC.
As of June 4, 2026, ONC stock price climbed to $279.93 with 96,339 million shares trading.
ONC has a beta of 0.79, meaning it tends to be less sensitive to market movements. ONC has a correlation of 0.05 to the broad based SPY ETF.
ONC has a market cap of $29.04 billion. This is considered a Large Cap stock.
Last quarter Beone Medicines Ltd. - American Depositary Shares reported $2 billion in Revenue and $3.24 earnings per share. This beat revenue expectation by $72 million and exceeded earnings estimates by $2.45.
The top ETF exchange traded funds that ONC belongs to (by Net Assets): IBB, FBT, CGGE, BBH, CGIE.
ONC has underperformed the market in the last year with a price return of +11.2% while the SPY ETF gained +28.2%. ONC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.8% and -9.3%, respectively, while the SPY returned +11.5% and +2.1%, respectively.
ONC support price is $273.45 and resistance is $284.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ONC shares will trade within this expected range on the day.